お電話でもお問い合わせください
 03-5860-2441
Report thumbnail
商品コード MM09147074898Q
出版日 2024/3/27
MarketsandMarkets
英文677 ページグローバル

IVD（体外診断）市場 - 製品別、サービス別、技術別、検体別、テストタイプ別、用途別：世界市場規模・市場予測レポート（〜2029年）

In Vitro Diagnostics Market by Product & Service (Instruments, Kits, Software), Technology (Immunoassay, Hematology, Urinalysis), Specimen (Blood, Saliva), Test Type, Application (Oncology, Autoimmune, CVD, Infectious Diseases) - Global Forecast to 2029


Report thumbnail
商品コード MM09147074898Q◆2025年3月版も出版されている時期ですので、お問い合わせ後すぐに確認いたします。
出版日 2024/3/27
MarketsandMarkets
英文 677 ページグローバル

IVD（体外診断）市場 - 製品別、サービス別、技術別、検体別、テストタイプ別、用途別：世界市場規模・市場予測レポート（〜2029年）

In Vitro Diagnostics Market by Product & Service (Instruments, Kits, Software), Technology (Immunoassay, Hematology, Urinalysis), Specimen (Blood, Saliva), Test Type, Application (Oncology, Autoimmune, CVD, Infectious Diseases) - Global Forecast to 2029


全体要約

2024年から2029年までの間に、世界のIVD市場は85.2億XX米ドルから119.4億XX米ドルに成長し、年間成長率は6.9%と予測されています。この成長は、高齢者人口の増加とそれに伴う慢性疾患や感染症の増加によって促進されています。特に、分子診断（MDx）技術は、感染症やがん、遺伝性疾患の増加によって最高の成長率が見込まれています。また、内分泌学分野も急速に成長すると予測され、糖尿病や甲状腺障害の増加により市場が牽引されます。

IVD市場は地域別に見ると、アジア太平洋地域が最も成長率が高いとされ、医療費の増加や高齢者人口の急増が要因です。市場の主要プレイヤーには、Roche Diagnostics（スイス）、Danaher Corporation（米国）、Abbott Laboratories（米国）、Siemens Healthineers（ドイツ）などが含まれています。市場参加者のプロフィールは、企業タイプ、役職、地域別に分かれており、詳細な分析が行われています。

関連する質問

1194億USD (2029年)

6.9% (2024年～2029年)

Roche Diagnostics, Danaher Corporation, Abbott Laboratories, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Qiagen N.V., QuidelOrtho Corporation, DiaSorin S.p.A., Illumina, Inc., Hologic, Inc., Revvity, Griffols, Werfen, Devyser, Chembio Diagnostics, Inc., Surmodics, Inc., Menarini Silicon Biosystems, SpeeDx Pty. Ltd., GENSPEED Biotech GmbH, Accelerate Diagnostics, Inc., Merck KGaA, Caris Life Sciences, Inc, Cellabs, J. Mitra & Co. Pvt. Ltd., Epitope Diagnostics, Boster Biological Technology, Enzo Biochem, Genetic Signatures, Savyon Diagnostics, Trivitron Healthcare, mdxhealth, Creative Diagnostics, InBios International, Inc., Maccura Biotechnology Co., Ltd., Vela Diagnostics, ARKRAY, Inc.

加齢に伴う疾患の増加、感染症の早期検出の重要性、分子診断技術の応用の拡大

概要

世界の体外診断市場は、2024年の852億ドルから2029年には1194億ドルに達すると予測されており、予測期間中の年平均成長率（CAGR）は6.9％です。世界的な高齢者人口の急増に伴い、加齢関連疾患の有病率は大幅に増加することが予想されています。糖尿病、癌、心血管疾患などの慢性疾患は、高齢者において一般的です。これらの疾患は継続的に監視し管理する必要があるため、診断テストの需要が高まっています。また、免疫系が弱まることにより、感染症にかかりやすくなります。感染症の効果的な治療は早期発見に依存しており、これはIVDテストによって可能になります。したがって、この要因はIVD市場の成長を大きく促進しています。
「分子診断（MDx）セグメントは、予測期間中に技術別の体外診断市場で最も高い成長率を示すと予測されています。」
IVD市場は技術に基づいて、免疫測定法、臨床化学、分子診断、血液学、微生物学、凝固および止血、尿検査、クロマトグラフィーおよび質量分析に分かれています。分子診断（MDx）セグメントは、予測期間中に最も高い成長率を記録することが見込まれています。この市場の成長は、感染症、癌、およびさまざまな遺伝性疾患の有病率の上昇、血液スクリーニングの需要の増加、および薬理遺伝学やポイントオブケアテストにおける分子診断技術の応用の増加によって主に推進されています。
「内分泌学セグメントは、予測期間中にアプリケーション別の体外診断市場で最高の成長率を記録すると予測されています。」
IVD市場は、感染症、腫瘍学、内分泌学、心臓病、血液スクリーニング、遺伝子検査、自己免疫疾患、アレルギー診断、薬物モニタリングおよび検査、骨およびミネラル障害、凝固検査、血液型の判定、その他のアプリケーションに分かれています。内分泌学セグメントは、体外診断市場の中で最も高い成長率を示すと予想されています。技術の進歩、糖尿病や甲状腺障害の発生率の増加、ライフスタイルの変化、これらの医療状態を管理するための自宅での検査の普及が、内分泌学アプリケーションにおけるIVD市場の成長の主要な推進要因です。
アジア太平洋：最も成長が早い地域の体外診断市場です。
グローバルIVD市場は、北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東およびアフリカ、GCC諸国にセグメント化されています。アジア太平洋市場は、予測期間中に最も高い成長率を示すと推定されています。医療支出の増加、高齢者人口の急成長、可処分所得の増加が、この地域を成長機会の魅力的な市場にしています。
IVD市場における主要参加者のプロフィールの内訳：
• 会社タイプ別： Tier 1 - 42％、Tier 2 - 30％、Tier 3 - 28％
・役職別：Cレベル - 46%、Dレベル - 23%、その他 - 31%
地域別：北米 - 23%、ヨーロッパ - 45%、アジア太平洋 - 28.3%、ラテンアメリカ - 3%、中東・アフリカ - 0.8%、GCC諸国 - 1.3%
この市場の主要なプレーヤーは、ロシュ・ダイアグノスティックス（スイス）、ダナハー・コーポレーション（米国）、アボット・ラボラトリーズ（米国）、シーメンス・ヘルスイニアーズ（ドイツ）、シスメックス（日本）、セルモ・フィッシャー・サイエンティフィック（米国）、ベクトン・ディッキンソン（米国）、バイオメリュー社（フランス）、バイオラッド・ラボラトリーズ（米国）、アジレント・テクノロジーズ（米国）、キアゲン（オランダ）、クイデルオルト社（米国）、ディアソリン（イタリア）、イルミナ（米国）、ホロジック（米国）、レバティ（米国）、グリフォルス（スペイン）、ワーフェン（スペイン）、デビイザー（スウェーデン）、ケンビオ・ダイアグノスティックス（米国）、サーモダイナミクス（米国）、メナリーニ・シリコンバイオシステムズ（イタリア）、スピードエックス（オーストラリア）、ジェンスピード・バイオテック（オーストリア）、アクセレート・ダイアグノスティクス（米国）、メルク・KGaA（ドイツ）、カリス・ライフサイエンス（米国）、セルラブス（オーストラリア）、J. ミトラ＆コー（インド）、エピトープ・ダイアグノスティクス（米国）、ボスター・バイオテクノロジー（米国）、エンゾ・バイオケム（米国）、ジェネティック・シグネチャーズ（オーストラリア）、サビオン・ダイアグノスティクス（イスラエル）、トリビトロン・ヘルスケア（インド）、mdxhealth（ベルギー）、クリエイティブ・ダイアグノスティクス（米国）、インバイオス・インターナショナル（米国）、マキューラ・バイオテクノロジー（中国）、ヴェラ・ダイアグノスティクス（シンガポール）、およびアークレイ（日本）です。
調査対象:
この研究報告書は、 in vitro 診断市場をテストタイプ（PoC テストと実験室テスト）、技術（分子診断、免疫測定法、凝固・止血、臨床化学、尿検査、クロマトグラフィー & 質量分析、微生物学、血液学）、製品とサービス（機器、試薬 & キット、データ管理ソフトウェアとサービス）、標本（尿、唾液、血液、血清、血漿、その他の標本）、エンドユーザー（製薬 & バイオテクノロジー企業、病院 & クリニック、血液バンク、学術機関、臨床検査室、在宅医療、その他のエンドユーザー）、アプリケーション（内分泌学、心臓病学、血液スクリーニング、血液型判定、自己免疫疾患、骨 & ミネラル障害、腫瘍学、凝固検査、遺伝子検査、感染症、アレルギー診断、薬物監視 & テスト、その他のアプリケーション）、地域（ラテンアメリカ、GCC諸国、ヨーロッパ、中東 & アフリカ、アジア太平洋、北アメリカ）によって分けています。
このレポートの範囲には、機会、課題、機会、そして制約を含む、IVD市場の成長に影響を与える重要な要因に関する包括的な詳細が含まれています。主要な業界プレイヤーのビジネス概要、提供される製品、重要な戦略、獲得及びパートナーシップ、製品の launches、そしてIVD市場に関連する最近の動向についての洞察を提供するために、徹底的な分析が行われました。この研究は、新興の体外診断スタートアップの競争環境を検討しています。
このレポートを購入する理由：
この報告書は、市場のリーダーや新規参入者が、全体の体外診断市場およびサブセグメントの収益数値の最も近い推定値に関する情報を得るのに役立ちます。この報告書は、利害関係者が競争環境を理解し、ビジネスをより良く位置付け、適切なゴー・ツー・マーケット戦略を計画するための洞察を得るのに役立ちます。また、この報告書は、利害関係者が市場の動向を理解し、主要な市場ドライバー、制約、課題、および機会に関する情報を提供します。
この報告書は、以下のポイントについての洞察を提供します。
• 主要な推進要因の分析：（高齢者人口の増加とそれに伴う慢性疾患・感染症の増加、迅速なPoC診断の出現）、制約（IVD市場における不利な償還シナリオ）、機会（疾患特異的バイオマーカーや検査の導入、新興市場での成長機会）、および課題（IVD市場に対する運営上の障壁）による体外診断市場の成長に影響を与える要素。
• 製品開発/革新：体外診断市場における研究開発活動、新製品の発売および承認に関する詳細な洞察。
• 市場開発: 有望な市場に関する包括的な情報 - この報告書は、さまざまな地域における体外診断市場を分析しています。
・市場の多様化：IVD市場における新製品、未開拓地域、最近の動向、投資に関する包括的な情報
• 競争評価: ロシュダイアグノスティクス（スイス）、ダナハーコーポレーション（米国）、アボットラボラトリーズ（米国）、シーメンスヘルスケア（ドイツ）、サーモフィッシャーサイエンティフィック（米国）などの主要プレーヤーの市場シェア、成長戦略、サービス提供の詳細な評価。

※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。

目次

  • 1 イントロダクション 82

    • 1.1 調査の目的 82
    • 1.2 市場の定義 82
    • 1.3 包含・除外事項 83
    • 1.4 市場範囲 84
      • 1.4.1 対象市場 84
      • 1.4.2 対象地域 85
      • 1.4.3 対象年 85
      • 1.4.4 通貨 86
    • 1.5 ステークホルダー 86
    • 1.6 変化のサマリー 86
      • 1.6.1 市場調整： 87
    • 1.7 リセッション時のインパクト 87

  • 2 調査手法 88

    • 2.1 リサーチデータ 88
      • 2.1.1 二次調査 89
        • 2.1.1.1 二次情報の主要データ 90
      • 2.1.2 一次データ 90
        • 2.1.2.1 一次情報 91
        • 2.1.2.2 一次情報の主要データ 91
        • 2.1.2.3 業界についての主な考察 93
    • 2.2 市場規模予測 94
      • 2.2.1 ボトムアップアプローチ 94
        • 2.2.1.1 アプローチ1：会社の収益推定アプローチ 95
    • 2.3 市場の内訳とデータのトライアンギュレーション 98
    • 2.4 市場シェア分析 99
    • 2.5 調査の前提 99
    • 2.6 成長率の前提 99
    • 2.7 調査上の制約 99
      • 2.7.1 手法上の制約 99
      • 2.7.2 範囲上の制約 100
    • 2.8 リスク評価 100
    • 2.9 リセッション時のインパクト分析 100

  • 3 エグゼクティブサマリー 101

  • 4 更なる考察 107

    • 4.1 IVD市場の概要 107
      • 4.1.7 ホロジック社 597
    • 4.2 北米：IVD市場：製品・サービス別、国別（2023年） 108
    • 4.3 体外診断薬市場：地域ミックス 108
    • 4.4 IVD市場、地理的側面での成長機会 109
    • 4.5 体外診断薬市場：新興国と先進国の比較 110

  • 5 市場概要 111

    • 5.1 イントロダクション 111
    • 5.2 市場ダイナミクス 111
      • 5.2.1 促進要因 112
      • 5.2.2 抑制要因 116
        • 5.2.2.1 不利な払い戻し 116
        • 5.2.2.2 厳格な規制 117
        • 5.2.2.3 高額な診断機器 118
      • 5.2.3 市場機会 118
        • 5.2.3.1 疾患特異的なバイオマーカーや検査の導入 118
        • 5.2.3.2 コンパニオン診断の意義が高まる 119
        • 5.2.3.3 新興国における成長機会 120
        • 5.2.3.4 免疫測定診断技術の向上 121
        • 5.2.3.5 デジタル化の流れ 121
      • 5.2.4 課題 122
        • 5.2.4.1 オペレーション上の障壁 122
    • 5.3 価格分析 123
    • 5.4 バリューチェーン分析 126
    • 5.5 サプライチェーン分析 127
    • 5.6 ポーターのファイブフォース分析 128
      • 5.6.1 競合・競争状況の激しさ 129
      • 5.6.2 サプライヤーの交渉力 129
      • 5.6.3 買い手の交渉力 129
      • 5.6.4 新規参入の脅威 129
      • 5.6.5 代替品の脅威 129
    • 5.7 エコシステム分析 130
      • 5.7.1 体外診断薬市場：エコシステムにおける役割 131
    • 5.8 規制当局、政府機関、その他組織 131
    • 5.9 規制分析 132
      • 5.9.1 北米 132
        • 5.9.1.1 米国 132
        • 5.9.1.2 カナダ 134
      • 5.9.2 ヨーロッパ 134
      • 5.9.3 アジア太平洋 136
        • 5.9.3.1 日本 136
        • 5.9.3.2 中国 137
        • 5.9.3.3 インド 138
        • 5.9.3.4 韓国 138
        • 5.9.3.5 インドネシア 139
      • 5.9.4 ロシア 139
      • 5.9.5 中東・アフリカ 140
        • 5.9.5.1 サウジアラビア 140
        • 5.9.5.2 アフリカ 141
      • 5.9.6 ラテンアメリカ 141
        • 5.9.6.1 メキシコ 141
        • 5.9.6.2 ブラジル 142
    • 5.10 特許分析 143
    • 5.11 顧客事業にインパクトのあるトレンド/ディスラプション 145
      • 5.11.1 体外診断薬市場の収益シフト 145
    • 5.12 主要なカンファレンスイベント 146
    • 5.13 技術分析 146
      • 5.13.1 体外診断市場：主要技術 146
      • 5.13.2 体外診断市場：隣接技術 147
    • 5.14 主なステークホルダーと購入基準 148
      • 5.14.1 購買プロセスにおける主要ステークホルダー 148
      • 5.14.2 購買基準 149
    • 5.15 取引分析・貿易分析 150
      • 5.15.1 IVD製品の貿易分析 150

  • 6 IVD市場、製品・サービス別 151

    • 6.1 イントロダクション 152
    • 6.2 試薬・キット 152
      • 6.2.1 迅速診断とポイントオブケア診断の需要増加が市場を牽引 152
    • 6.3 インスツルメンツ 156
      • 6.3.1 自動化トレンドの高まりが市場を牽引 156
    • 6.4 データ管理ソフトウェアとサービス 160
      • 6.4.1 市場の成長を支える業務効率の改善能力 160

  • 7 IVDの市場、技術別 165

    • 7.1 イントロダクション 166
    • 7.2 免疫検定 166
      • 7.2.1 酵素結合免疫吸着測定法(ELISA) 171
      • 7.2.2 ケミルミネッセンス免疫測定法 174
        • 7.2.2.1 高感度と広い検出範囲で市場を活性化 174
      • 7.2.3 免疫蛍光アッセイ 178
        • 7.2.3.1 医学研究におけるHIV抗体診断が市場成長を支える 178
      • 7.2.4 ラピッドテスト 181
        • 7.2.4.1 救急医療での利用増が市場を牽引 181
      • 7.2.5 酵素結合免疫スポットアッセイ（エリスポット） 185
        • 7.2.5.1 迅速なサンプル分析と高い機能性が需要を後押し 185
      • 7.2.6 ウェスタンブロット法 188
        • 7.2.6.1 結果検証のゴールドスタンダードが需要を高める 188
      • 7.2.7 その他の免疫測定技術 191
    • 7.3 クリニカルケミストリー 194
      • 7.3.1 メタボリックベーシックパネル 199
        • 7.3.1.1 糖尿病有病率の上昇が需要を押し上げる 199
      • 7.3.2 肝臓のパネル 202
        • 7.3.2.1 肝硬変とウイルス性肝炎の有病率の増加が市場を刺激 202
      • 7.3.3 腎臓のプロファイル 205
      • 7.3.4 脂質プロファイル 208
      • 7.3.5 甲状腺機能検査パネル 211
        • 7.3.5.1 甲状腺関連疾患の高い発生率が市場の成長を支える 211
      • 7.3.6 電解質パネル 214
        • 7.3.6.1 高血圧と心不全を診断し、摂取をサポートする能力 214
      • 7.3.7 スペシャリティケミカルテスト 217
    • 7.4 分子診断 220
      • 7.4.1 ポリメラーゼ連鎖反応(PCR) 225
        • 7.4.1.1 RT-PCR検査の高い特異性が市場を牽引 225
      • 7.4.2 等温核酸増幅技術(inaat) 228
        • 7.4.2.1 市場を牽引するコストメリット 228
      • 7.4.3 DNAシーケンスと次世代シーケンス（NGS） 232
        • 7.4.3.1 NGSベースの検査コストの低下が需要を押し上げる 232
      • 7.4.4 In situ ハイブリダイゼーション（ISH） 235
        • 7.4.4.1 がんと遺伝性疾患の有病率の上昇が市場を牽引 235
      • 7.4.5 DNAマイクロアレイ 238
        • 7.4.5.1 市場の成長を支える高解像度とスループット能力 238
      • 7.4.6 その他の分子診断技術 241
    • 7.5 ヘマトロジー 244
      • 7.5.1 幹細胞研究への関心の高まりが需要を押し上げる 244
    • 7.6 微生物学 247
      • 7.6.1 微生物感染症の増加が市場を活性化させる 247
    • 7.7 凝固・止血 250
    • 7.8 尿検査 253
      • 7.8.1 ウツ病罹患率の上昇が市場成長を支える 253
    • 7.9 クロマトグラフィー＆質量分析 256
      • 7.9.1 手法の改善と技術革新が市場を活性化させる 256

  • 8 IVD市場：検体別 260

    • 8.1 イントロダクション 261
    • 8.2 血液、血清、血漿 261
      • 8.2.1 慢性疾患診断の高い信頼性が市場を牽引 261
    • 8.3 唾液 264
      • 8.3.1 免疫測定に基づく検査の進歩が市場の成長を支える 264
    • 8.4 尿 267
      • 8.4.1 違法薬物検査への利用が増加し、需要を押し上げる 267
    • 8.5 その他の標本 270

  • 9 IVDの市場、テストタイプ別 274

    • 9.1 イントロダクション 275
    • 9.2 ラボラトリーテスト 275
    • 9.3 ポイントオブケア検査 278
      • 9.3.1 迅速な結果と高い利便性が需要を高める 278

  • 10 IVDの市場、用途別 282

    • 10.1 イントロダクション 283
    • 10.2 感染症 284
      • 10.2.1 結核と腸チフスの増加が需要を押し上げる 284
    • 10.3 オンコロジー 287
      • 10.3.1 乳がん罹患率の高さが市場を牽引 287
    • 10.4 内分泌学 290
      • 10.4.1 糖尿病と甲状腺関連疾患の増加が市場を牽引 290
    • 10.5 循環器内科 293
      • 10.5.1 CVD検出におけるイムノアッセイの使用増加が市場を後押し 293
    • 10.6 血液スクリーニング 297
      • 10.6.1 HIVと梅毒の罹患率の増加が市場成長を支える 297
    • 10.7 遺伝子検査 300
      • 10.7.1 市場の成長を支える希少疾患の診断 300
    • 10.8 自己免疫疾患 303
      • 10.8.1 自己免疫測定への需要の高まりが市場を牽引 303
    • 10.9 アレルギー診断 306
    • 10.10 薬物モニタリングと検査 309
      • 10.10.1 違法薬物消費の増加が市場を牽引 309
    • 10.11 骨・ミネラル疾患 313
      • 10.11.1 骨粗鬆症患者の増加が市場に拍車をかける 313
    • 10.12 凝固検査 317
      • 10.12.1 血友病患者数の増加が需要を押し上げる 317
    • 10.13 血液型タイピング 320
      • 10.13.1 手術件数の増加が市場の需要を支える 320
    • 10.14 その他の用途 323

  • 11 IVDの市場、エンドユーザー別 327

    • 11.1 イントロダクション 328
    • 11.2 病院・クリニック 328
      • 11.2.1 慢性疾患の増加が需要を押し上げる 328
    • 11.3 クリニカルラボラトリーズ 332
      • 11.3.1 大規模リファレンス・ラボ 335
        • 11.3.1.1 市場を推進するための特定の高度なテストを実施する能力 335
      • 11.3.2 中小型研究ラボ 338
        • 11.3.2.1 市場成長を支えるPOC機器導入への注目の高まり 338
    • 11.4 血液バンク 341
      • 11.4.1 ELISA検査の普及が市場を牽引 341
    • 11.5 ホームケア設定 344
      • 11.5.1 便利な在宅抗原検査の普及が需要を押し上げる 344
    • 11.6 製薬会社・バイオテクノロジー企業 348
      • 11.6.1 INCREASING FOCUS ON DRUG DISCOVERY DEVELOPMENT TO DRIVE MARKET 348
    • 11.7 学術機関 351
      • 11.7.1 製品開発のための産学共同研究の増加が市場成長を支える 351
    • 11.8 その他のエンドユーザー 354

  • 12 IVDの市場、地域別 358

    • 12.1 イントロダクション 359
    • 12.2 北米 360
      • 12.2.1 北米：リセッション時のインパクト 360
      • 12.2.2 米国 367
      • 12.2.3 カナダ 373
        • 12.2.3.1 早期疾病診断のための有利な資金調達イニシアティブが市場を牽引 373
    • 12.3 ヨーロッパ 380
      • 12.3.1 ヨーロッパ：リセッション時のインパクト 381
      • 12.3.2 ドイツ 388
        • 12.3.2.1 臨床診断研究への投資の増加が市場を牽引 388
      • 12.3.3 フランス 394
      • 12.3.4 英国 399
        • 12.3.4.1 ゲノムに基づく検査の普及が市場を牽引 399
      • 12.3.5 イタリア 406
      • 12.3.6 スペイン 412
        • 12.3.6.1 技術的に高度な免疫測定システムの採用が市場を牽引 412
      • 12.3.7 ロシア 417
        • 12.3.7.1 呼吸器感染症の高い発生率が需要を押し上げる 417
      • 12.3.8 スイス 423
        • 12.3.8.1 慢性疾患の蔓延が市場成長を支える 423
      • 12.3.9 その他のヨーロッパ 429
    • 12.4 アジア太平洋 436
      • 12.4.1 アジア太平洋：リセッション時のインパクト 444
      • 12.4.2 日本 444
        • 12.4.2.1 イムノアッセイへの研究投資の増加が市場を牽引 444
      • 12.4.3 中国 450
        • 12.4.3.1 予防医療への関心の高まりが需要を押し上げる 450
      • 12.4.4 インド 455
        • 12.4.4.1 糖尿病と癌の罹患率の増加が市場を牽引 455
      • 12.4.5 韓国 461
      • 12.4.6 オーストラリア 467
      • 12.4.7 その他のアジア太平洋 474
    • 12.5 ラテンアメリカ 480
      • 12.5.1 ラテンアメリカ：リセッション時のインパクト 480
      • 12.5.2 ブラジル 486
        • 12.5.2.1 糖尿病有病率の上昇が体外診断用医薬品の需要を押し上げる 486
      • 12.5.3 メキシコ 491
        • 12.5.3.1 臨床検査室を設立し、普及を促進 491
      • 12.5.4 その他のラテンアメリカ 497
    • 12.6 中東・アフリカ 503
      • 12.6.1 出生前検査とがん検査への関心の高まりが市場を牽引 503
      • 12.6.2 中東・アフリカ：リセッション時のインパクト 508
    • 12.7 GCC地域 509
      • 12.7.1 GCC地域：リセッション時のインパクト 509
      • 12.7.2 サウジアラビア王国（KSA） 515
        • 12.7.2.1 政府医療費の増加が需要を押し上げる 515
      • 12.7.3 アラブ首長国連邦（uae） 521
        • 12.7.3.1 医療インフラの整備が市場成長を支える 521
      • 12.7.4 その他GCC地域 527

  • 13 競合情勢 533

    • 13.1 概要 533
    • 13.2 主要プレイヤーの戦略 533
    • 13.3 主要市場プレイヤーの収益シェア分析 535
    • 13.4 市場シェア分析 536
    • 13.5 企業評価マトリックス：主要企業 <num4>年 538
      • 13.5.1 STARS 538
      • 13.5.2 EMERGING LEADERS 538
      • 13.5.3 PERVASIVE PLAYERS 538
      • 13.5.4 PARTICIPANTS 538
      • 13.5.5 主要プレイヤーの企業フットプリント分析 540
    • 13.6 START UP/SME EVALUATION MATRIX, 2023 544
      • 13.6.1 PROGRESSIVE COMPANIES 544
      • 13.6.2 RESPONSIVE COMPANIES 544
      • 13.6.3 DYNAMIC COMPANIES 544
      • 13.6.4 STARTING BLOCKS 544
      • 13.6.5 新興企業/中小企業の競合ベンチマーキング 545
    • 13.7 競合シナリオ 546
      • 13.7.1 製品およびサービスの発表と承認 546
      • 13.7.2 ディール 547
      • 13.7.3 拡大 548
      • 13.7.4 その他の展開 549
    • 13.8 BRAND/PRODUCT COMPARISON 550

  • 14 企業プロファイル 551

    • 14.1 主要企業 551
      • 14.1.1 DANAHER CORPORATION 551
      • 14.1.2 ROCHE DIAGNOSTICS 558
      • 14.1.3 ABBOTT 568
      • 14.1.4 SIEMENS HEALTHINEERS AG 576
      • 14.1.5 THERMO FISHER SCIENTIFIC INC 583
      • 14.1.6 ILLUMINA, INC 591
      • 14.1.8 BIO-RAD LABORATORIES, INC 601
      • 14.1.9 BIOMÉRIEUX 606
      • 14.1.10 SYSMEX CORPORATION 612
      • 14.1.11 REVVITY 616
      • 14.1.12 BECTON, DICKINSON AND COMPANY 622
      • 14.1.13 AGILENT TECHNOLOGIES, INC 628
      • 14.1.14 QIAGEN N.V 635
      • 14.1.15 DIASORIN S.P.A 644
      • 14.1.16 GRIFOLS S.A 652
      • 14.1.17 WERFEN S.A 655
      • 14.1.18 QUIDELORTHO CORPORATION 659
    • 14.2 他の有力企業 666
      • 14.2.1 DEVYSER 666
      • 14.2.2 CHEMBIO DIAGNOSTICS, INC 668
      • 14.2.3 SURMODICS, INC 671
      • 14.2.4 MENARINI SILICON BIOSYSTEMS 674
      • 14.2.5 SPEEDX PTY. LTD 675
      • 14.2.6 GENSPEED BIOTECH GMBH 676
      • 14.2.7 MERCK KGAA 677
      • 14.2.8 CARIS LIFE SCIENCES, INC 679
      • 14.2.9 ARKRAY, INC 681
      • 14.2.10 ACCELERATE DIAGNOSTICS, INC 682
      • 14.2.11 CELLABS 683
      • 14.2.12 J. MITRA & CO. PVT. LTD 684
      • 14.2.13 EPITOPE DIAGNOSTICS, INC 685
      • 14.2.14 BOSTER BIOLOGICAL TECHNOLOGY 686
      • 14.2.15 ENZO BIOCHEM, INC 687
      • 14.2.16 GENETIC SIGNATURES 688
      • 14.2.17 SAVYON DIAGNOSTICS LTD 689
      • 14.2.18 TRIVITRON HEALTHCARE 690
      • 14.2.19 MDXHEALTH SA 691
      • 14.2.20 CREATIVE DIAGNOSTICS 692
      • 14.2.21 INBIOS INTERNATIONAL, INC 693
      • 14.2.22 MACCURA BIOTECHNOLOGY CO., LTD 694
      • 14.2.23 VELA DIAGNOSTICS 695

  • 15 付録 696

    • 15.1 ディスカッションガイド 696
    • 15.2 ナレッジストア : MarketAndMarketのサブスクリプションポータル 703
    • 15.3 カスタマイズオプション 705
    • 15.4 関連レポート 706
    • 15.5 執筆者の詳細 707

※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”

Description

The global in vitro diagnostics market is projected to reach USD 119.4 billion by 2029 from USD 85.2 billion in 2024, at a CAGR of 6.9% during the forecast period. With the rapid growth in the geriatric population globally, the prevalence of age-associated diseases is expected to increase significantly. Chronic conditions that include diabetes, cancer, and cardiovascular disease are more common in old age. As these diseases need to be continuously monitored and managed, there is an increasing need for diagnostic tests. Also, due to a weakened immune system, people get increasingly susceptible to several infectious diseases. Effective treatment of infectious diseases depends on early detection, which made possible by IVD tests. Hence, this factor is significantly inducing growth of the IVD market. “Molecular diagnostics (MDx) segment is projected to witness highest growth rate in the in vitro diagnostics market, by technology, during the forecast period.” Based on the technology the IVD market is bifurcated into immunoassays, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, and chromatography & mass spectrometry. The molecular diagnostics (MDx) segment is estimated to register the highest growth rate during the forecast period. Growth in this market is majorly driven by the rising prevalence of infectious diseases, cancer, and various genetic disorders; growing demand for blood screening; and increasing applications of molecular diagnostic technologies in pharmacogenetics and point-of-care testing. “Endocrinology segment is projected to register highest growth rate in the in vitro diagnostics market, by application, during the forecast period.” The IVD market is bifurcated into infectious diseases, oncology, endocrinology, cardiology, blood screening, genetic testing, autoimmune diseases, allergy diagnostics, drug monitoring & testing, bone & mineral disorders, coagulation testing, blood group typing, and other applications. The endocrinology segment is expected to grow at the highest rate within the in vitro diagnostics market. Technological advancements, the increasing incidence of diabetes and thyroid disorders, changing lifestyles, and the availability of home tests to control these medical conditions are the major drivers for the growth of the IVD market for endocrinology applications. “Asia Pacific: The fastest-growing region in vitro diagnostics market.” The global IVD market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries. The Asia Pacific market is estimated to witness the highest growth rate during the forecast period. The rising healthcare spending, rapidly growing geriatric populations, and increasing disposable income make this region a lucrative market for growth opportunities. The break-up of the profile of primary participants in the IVD market: • By Company Type: Tier 1 - 42%, Tier 2 - 30%, and Tier 3 – 28% • By Designation: C-level - 46%, D-level - 23%, and Others - 31% • By Region: North America - 23%, Europe - 45%, Asia Pacific – 28.3%, Latin America- 3%, Middle East & Africa – 0.8%, GCC Countries – 1.3% The key players in this market are Roche Diagnostics (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Siemens Healthineers (Germany), Sysmex Corporation (Japan), Thermo Fisher Scientific, Inc. (US), Becton, Dickinson and Company (US), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), Qiagen N.V. (Netherlands), QuidelOrtho Corporation (US), DiaSorin S.p.A. (Italy), Illumina, Inc. (US), Hologic, Inc. (US), Revvity (US), Griffols (Spain), Werfen (Spain), Devyser (Sweden), Chembio Diagnostics, Inc. (US). Surmodics, Inc. (US), Menarini Silicon Biosystems (Italy), SpeeDx Pty. Ltd. (Australia), GENSPEED Biotech GmbH (Austria), Accelerate Diagnostics, Inc. (US), Merck KGaA (Germany), Caris Life Sciences, Inc (US), Cellabs (Australia), J. Mitra & Co. Pvt. Ltd. (India), Epitope Diagnostics (US), Boster Biological Technology (US), Enzo Biochem (US), Genetic Signatures (Australia), Savyon Diagnostics (Israel), Trivitron Healthcare (India), mdxhealth (Belgium), Creative Diagnostics (US), InBios International, Inc. (US), Maccura Biotechnology Co., Ltd. (China), Vela Diagnostics (Singapore), and ARKRAY, Inc. (Japan) Research Coverage: This research report divided the in vitro diagnostics market by test type (PoC tests and laboratory tests), by technology (molecular diagnostics, immunoassays, coagulation & hemostasis, clinical chemistry, urinalysis, chromatography & mass spectrometry, microbiology, and hematology), by product & services (instruments, reagents & kits, and data management software and services), specimen (urine, saliva, blood, serum, and plasma, and other specimens), by end user (pharmaceutical & biotechnology companies, hospital & clinics, blood banks, academic institutes, clinical laboratories, home care settings, and other end users), by application (endocrinology, cardiology, blood screening, blood group typing, autoimmune diseases, bone & mineral disorders, oncology, coagulation testing, genetic testing, infectious diseases, allergy diagnostics, drug monitoring & testing, and other applications), and by region (Latin America, the GCC Countries, Europe, Middle East & Africa, Asia Pacific, and North America) The report's coverage includes comprehensive details about the key factors impacting the growth of the IVD market, including opportunities, challenges, opportunities, and restraints. To offer insights into their business overview, products offered, significant strategies, acquisitions and partnerships, product launches, and recent developments related to the IVD market, a thorough analysis of the major industry players has been conducted. This study examines the competitive landscape of emerging in vitro diagnostics startups. Reasons to buy this report: The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall in vitro diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities. The report provides insights on the following pointers: • Analysis of key drivers: (Increasing geriatric population and subsequent rise in chronic & infectious diseases, and Emergence of rapid PoC diagnostics), restraints (Unfavorable reimbursement scenario for IVD market), opportunities (Introduction of disease-specific biomarkers and tests, and Growth opportunities in emerging markets), and challenges (Operational barriers to the IVD market) influencing the growth of the in vitro diagnostics market. • Product Development/Innovation: Detailed insights on research & development activities, and new product launches and approvals in the in vitro diagnostics market. • Market Development: Comprehensive information about lucrative markets – the report analyses the in vitro diagnostics market across varied regions. • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the IVD market • Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Roche Diagnostics (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (US) among others in the IVD market strategies.

Table of Contents

  • 1 INTRODUCTION 82

    • 1.1 STUDY OBJECTIVES 82
    • 1.2 MARKET DEFINITION 82
    • 1.3 INCLUSIONS & EXCLUSIONS 83
    • 1.4 MARKET SCOPE 84
      • 1.4.1 MARKETS COVERED 84
      • 1.4.2 REGIONS COVERED 85
      • 1.4.3 YEARS CONSIDERED 85
      • 1.4.4 CURRENCY CONSIDERED 86
    • 1.5 MARKET STAKEHOLDERS 86
    • 1.6 SUMMARY OF CHANGES 86
      • 1.6.1 MARKET RECONCILIATION: 87
    • 1.7 RECESSION IMPACT 87

  • 2 RESEARCH METHODOLOGY 88

    • 2.1 RESEARCH DATA 88
      • 2.1.1 SECONDARY RESEARCH 89
        • 2.1.1.1 Key data from secondary sources 90
      • 2.1.2 PRIMARY DATA 90
        • 2.1.2.1 Primary sources 91
        • 2.1.2.2 Key data from primary sources 91
        • 2.1.2.3 Key industry insights 93
    • 2.2 MARKET SIZE ESTIMATION 94
      • 2.2.1 BOTTOM-UP APPROACH 94
        • 2.2.1.1 Approach 1: Company revenue estimation approach 95
    • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 98
    • 2.4 MARKET SHARE ANALYSIS 99
    • 2.5 STUDY ASSUMPTIONS 99
    • 2.6 GROWTH RATE ASSUMPTIONS 99
    • 2.7 RESEARCH LIMITATIONS 99
      • 2.7.1 METHODOLOGY-RELATED LIMITATIONS 99
      • 2.7.2 SCOPE-RELATED LIMITATIONS 100
    • 2.8 RISK ASSESSMENT 100
    • 2.9 RECESSION IMPACT ANALYSIS 100

  • 3 EXECUTIVE SUMMARY 101

  • 4 PREMIUM INSIGHTS 107

    • 4.1 IN VITRO DIAGNOSTICS MARKET OVERVIEW 107
      • 4.1.7 HOLOGIC, INC 597
    • 4.2 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2023) 108
    • 4.3 IN VITRO DIAGNOSTICS MARKET: REGIONAL MIX 108
    • 4.4 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 109
    • 4.5 IN VITRO DIAGNOSTICS MARKET: EMERGING ECONOMIES VS. DEVELOPED ECONOMIES 110

  • 5 MARKET OVERVIEW 111

    • 5.1 INTRODUCTION 111
    • 5.2 MARKET DYNAMICS 111
      • 5.2.1 DRIVERS 112
        • 5.2.1.1 Increasing geriatric population and subsequent rise in chronic & infectious diseases 112
        • 5.2.1.2 Gradual shift from centralized testing to point-of-care testing 113
        • 5.2.1.3 Growing awareness of early disease diagnosis in emerging economies 114
        • 5.2.1.4 Emergence of rapid PoC technologies and rising adoption of automated analyzers 115
        • 5.2.1.5 Growing preference for personalized medicine 115
        • 5.2.1.6 Increasing funding for R&D activities 116
      • 5.2.2 RESTRAINTS 116
        • 5.2.2.1 Unfavorable reimbursements 116
        • 5.2.2.2 Stringent regulatory requirements 117
        • 5.2.2.3 High cost of diagnostic equipment 118
      • 5.2.3 OPPORTUNITIES 118
        • 5.2.3.1 Introduction of disease-specific biomarkers and tests 118
        • 5.2.3.2 Growing significance of companion diagnostics 119
        • 5.2.3.3 Growth opportunities in emerging markets 120
        • 5.2.3.4 Improvements in immunoassay diagnostic technologies 121
        • 5.2.3.5 Trend of digitalization 121
      • 5.2.4 CHALLENGES 122
        • 5.2.4.1 Operational barriers 122
    • 5.3 PRICING ANALYSIS 123
      • 5.3.1 INDICATIVE AVERAGE SELLING PRICE OF REAGENTS & KITS (USD), BY REGION 123
      • 5.3.2 AVERAGE SELLING PRICE OF IMMUNOASSAY ANALYZERS (USD) 123
      • 5.3.3 AVERAGE SELLING PRICE OF LATERAL FLOW ANALYZERS (USD) 124
      • 5.3.4 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTICS (USD) 124
      • 5.3.5 AVERAGE SELLING PRICE OF CLINICAL CHEMISTRY ANALYZERS (USD) 125
    • 5.4 VALUE CHAIN ANALYSIS 126
    • 5.5 SUPPLY CHAIN ANALYSIS 127
    • 5.6 PORTER’S FIVE FORCES ANALYSIS 128
      • 5.6.1 INTENSITY OF COMPETITIVE RIVALRY 129
      • 5.6.2 BARGAINING POWER OF SUPPLIERS 129
      • 5.6.3 BARGAINING POWER OF BUYERS 129
      • 5.6.4 THREAT OF NEW ENTRANTS 129
      • 5.6.5 THREAT OF SUBSTITUTES 129
    • 5.7 ECOSYSTEM ANALYSIS 130
      • 5.7.1 IN VITRO DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM 131
    • 5.8 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 131
    • 5.9 REGULATORY ANALYSIS 132
      • 5.9.1 NORTH AMERICA 132
        • 5.9.1.1 US 132
        • 5.9.1.2 Canada 134
      • 5.9.2 EUROPE 134
      • 5.9.3 ASIA PACIFIC 136
        • 5.9.3.1 Japan 136
        • 5.9.3.2 China 137
        • 5.9.3.3 India 138
        • 5.9.3.4 South Korea 138
        • 5.9.3.5 Indonesia 139
      • 5.9.4 RUSSIA 139
      • 5.9.5 MIDDLE EAST & AFRICA 140
        • 5.9.5.1 Saudi Arabia 140
        • 5.9.5.2 Africa 141
      • 5.9.6 LATIN AMERICA 141
        • 5.9.6.1 Mexico 141
        • 5.9.6.2 Brazil 142
    • 5.10 PATENT ANALYSIS 143
    • 5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 145
      • 5.11.1 REVENUE SHIFT FOR IN VITRO DIAGNOSTICS MARKET 145
    • 5.12 KEY CONFERENCES & EVENTS 146
    • 5.13 TECHNOLOGY ANALYSIS 146
      • 5.13.1 IN VITRO DIAGNOSTICS MARKET: KEY TECHNOLOGIES 146
      • 5.13.2 IN VITRO DIAGNOSTICS MARKET: ADJACENT TECHNOLOGIES 147
    • 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 148
      • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 148
      • 5.14.2 BUYING CRITERIA 149
    • 5.15 TRADE ANALYSIS 150
      • 5.15.1 TRADE ANALYSIS FOR IVD PRODUCTS 150

  • 6 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 151

    • 6.1 INTRODUCTION 152
    • 6.2 REAGENTS & KITS 152
      • 6.2.1 INCREASING DEMAND FOR RAPID AND POINT-OF-CARE DIAGNOSTICS TO DRIVE MARKET 152
    • 6.3 INSTRUMENTS 156
      • 6.3.1 RISING TREND OF AUTOMATION TO DRIVE MARKET 156
    • 6.4 DATA MANAGEMENT SOFTWARE AND SERVICES 160
      • 6.4.1 ABILITY TO IMPROVE OPERATIONAL EFFICIENCY TO SUPPORT MARKET GROWTH 160

  • 7 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 165

    • 7.1 INTRODUCTION 166
    • 7.2 IMMUNOASSAYS 166
      • 7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA) 171
        • 7.2.1.1 Utilization in viral disease diagnostics and drug discovery to boost demand 171
      • 7.2.2 CHEMILUMINESCENCE IMMUNOASSAYS 174
        • 7.2.2.1 High sensitivity and wide detection range to fuel market 174
      • 7.2.3 IMMUNOFLUORESCENCE ASSAYS 178
        • 7.2.3.1 HIV antibody diagnosis in medical research to support market growth 178
      • 7.2.4 RAPID TESTS 181
        • 7.2.4.1 Rising usage in emergency care to drive market 181
      • 7.2.5 ENZYME-LINKED IMMUNOSPOT ASSAYS (ELISPOT) 185
        • 7.2.5.1 Rapid analysis of samples and high functionality to boost demand 185
      • 7.2.6 WESTERN BLOTTING 188
        • 7.2.6.1 Gold standard for result validation to boost demand 188
      • 7.2.7 OTHER IMMUNOASSAY TECHNOLOGIES 191
    • 7.3 CLINICAL CHEMISTRY 194
      • 7.3.1 BASIC METABOLIC PANELS 199
        • 7.3.1.1 Rising prevalence of diabetes to boost demand 199
      • 7.3.2 LIVER PANELS 202
        • 7.3.2.1 Rising prevalence of cirrhosis and viral hepatitis to fuel market 202
      • 7.3.3 RENAL PROFILES 205
        • 7.3.3.1 Ability to monitor cytokines & chemokines in urine to propel market 205
      • 7.3.4 LIPID PROFILES 208
        • 7.3.4.1 Determination of total cholesterol and risk status for CVD to boost demand 208
      • 7.3.5 THYROID FUNCTION PANELS 211
        • 7.3.5.1 High incidence of thyroid-related disorders to support market growth 211
      • 7.3.6 ELECTROLYTE PANELS 214
        • 7.3.6.1 Ability to diagnose hypertension and heart failure to support uptake 214
      • 7.3.7 SPECIALTY CHEMICAL TESTS 217
        • 7.3.7.1 Inclusion of immunosuppressant drug monitoring and drugs of abuse to support market growth 217
    • 7.4 MOLECULAR DIAGNOSTICS 220
      • 7.4.1 POLYMERASE CHAIN REACTION (PCR) 225
        • 7.4.1.1 High specificity of RT-PCR tests to drive market 225
      • 7.4.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT) 228
        • 7.4.2.1 Cost benefits to drive market 228
      • 7.4.3 DNA SEQUENCING & NEXT-GENERATION SEQUENCING (NGS) 232
        • 7.4.3.1 Declining costs of NGS-based tests to boost demand 232
      • 7.4.4 IN SITU HYBRIDIZATION (ISH) 235
        • 7.4.4.1 Rising prevalence of cancer and genetic disorders to drive market 235
      • 7.4.5 DNA MICROARRAYS 238
        • 7.4.5.1 High resolution and throughput capabilities to support market growth 238
      • 7.4.6 OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES 241
    • 7.5 HEMATOLOGY 244
      • 7.5.1 GROWING FOCUS ON STEM CELL RESEARCH TO BOOST DEMAND 244
    • 7.6 MICROBIOLOGY 247
      • 7.6.1 RISING PREVALENCE OF MICROBIAL INFECTIONS TO FUEL MARKET 247
    • 7.7 COAGULATION & HEMOSTASIS 250
      • 7.7.1 GROWING USE OF ANTICOAGULATION THERAPY IN SURGICAL PROCEDURES TO DRIVE MARKET 250
    • 7.8 URINALYSIS 253
      • 7.8.1 RISING INCIDENCE OF UTIS TO SUPPORT MARKET GROWTH 253
    • 7.9 CHROMATOGRAPHY & MASS SPECTROMETRY 256
      • 7.9.1 METHODOLOGICAL IMPROVEMENTS AND TECHNOLOGICAL INNOVATIONS TO FUEL MARKET 256

  • 8 IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN 260

    • 8.1 INTRODUCTION 261
    • 8.2 BLOOD, SERUM, AND PLASMA 261
      • 8.2.1 HIGH RELIABILITY FOR CHRONIC DISEASE DIAGNOSIS TO PROPEL MARKET 261
    • 8.3 SALIVA 264
      • 8.3.1 ADVANCEMENTS IN IMMUNOASSAY-BASED TESTS TO SUPPORT MARKET GROWTH 264
    • 8.4 URINE 267
      • 8.4.1 INCREASING UTILIZATION IN ILLICIT DRUG TESTING TO BOOST DEMAND 267
    • 8.5 OTHER SPECIMENS 270

  • 9 IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE 274

    • 9.1 INTRODUCTION 275
    • 9.2 LABORATORY TESTS 275
      • 9.2.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND GROWING FOCUS ON EARLY DISEASE DETECTION TO PROPEL MARKET 275
    • 9.3 POINT-OF-CARE TESTS 278
      • 9.3.1 RAPID RESULTS AND HIGH CONVENIENCE TO BOOST DEMAND 278

  • 10 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION 282

    • 10.1 INTRODUCTION 283
    • 10.2 INFECTIOUS DISEASES 284
      • 10.2.1 INCREASING PREVALENCE OF TB AND TYPHOID TO BOOST DEMAND 284
    • 10.3 ONCOLOGY 287
      • 10.3.1 HIGH INCIDENCE OF BREAST CANCER TO PROPEL MARKET 287
    • 10.4 ENDOCRINOLOGY 290
      • 10.4.1 RISING PREVALENCE OF DIABETES AND THYROID-RELATED DISORDERS TO DRIVE MARKET 290
    • 10.5 CARDIOLOGY 293
      • 10.5.1 INCREASING USE OF IMMUNOASSAYS IN CVD DETECTION TO FUEL MARKET 293
    • 10.6 BLOOD SCREENING 297
      • 10.6.1 RISING INCIDENCE OF HIV AND SYPHILIS TO SUPPORT MARKET GROWTH 297
    • 10.7 GENETIC TESTING 300
      • 10.7.1 DIAGNOSIS OF RARE DISEASES TO SUPPORT MARKET GROWTH 300
    • 10.8 AUTOIMMUNE DISEASES 303
      • 10.8.1 GROWING DEMAND FOR AUTOIMMUNITY ASSAYS TO DRIVE MARKET 303
    • 10.9 ALLERGY DIAGNOSTICS 306
      • 10.9.1 ABILITY TO DETERMINE FOOD & DRUG ALLERGIES TO SUPPORT MARKET GROWTH 306
    • 10.10 DRUG MONITORING & TESTING 309
      • 10.10.1 INCREASING ILLICIT DRUG CONSUMPTION TO DRIVE MARKET 309
    • 10.11 BONE & MINERAL DISORDERS 313
      • 10.11.1 RISING CASES OF OSTEOPOROSIS TO FUEL MARKET 313
    • 10.12 COAGULATION TESTING 317
      • 10.12.1 INCREASING PREVALENCE OF HEMOPHILIA TO BOOST DEMAND 317
    • 10.13 BLOOD GROUP TYPING 320
      • 10.13.1 RISING NUMBER OF SURGICAL PROCEDURES TO SUPPORT MARKET DEMAND 320
    • 10.14 OTHER APPLICATIONS 323

  • 11 IN VITRO DIAGNOSTICS MARKET, BY END USER 327

    • 11.1 INTRODUCTION 328
    • 11.2 HOSPITALS & CLINICS 328
      • 11.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO BOOST DEMAND 328
    • 11.3 CLINICAL LABORATORIES 332
      • 11.3.1 LARGE REFERENCE LABORATORIES 335
        • 11.3.1.1 Capability to conduct specific advanced tests to propel market 335
      • 11.3.2 SMALL AND MEDIUM-SIZED LABORATORIES 338
        • 11.3.2.1 Growing focus on POC device adoption to support market growth 338
    • 11.4 BLOOD BANKS 341
      • 11.4.1 RISING UTILIZATION OF ELISA TESTS TO PROPEL MARKET 341
    • 11.5 HOME CARE SETTINGS 344
      • 11.5.1 ADOPTION OF CONVENIENT AT-HOME ANTIGEN TESTS TO BOOST DEMAND 344
    • 11.6 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 348
      • 11.6.1 INCREASING FOCUS ON DRUG DISCOVERY DEVELOPMENT TO DRIVE MARKET 348
    • 11.7 ACADEMIC INSTITUTES 351
      • 11.7.1 RISING INDUSTRY-ACADEMIA COLLABORATIONS FOR PRODUCT DEVELOPMENT TO SUPPORT MARKET GROWTH 351
    • 11.8 OTHER END USERS 354

  • 12 IN VITRO DIAGNOSTICS MARKET, BY REGION 358

    • 12.1 INTRODUCTION 359
    • 12.2 NORTH AMERICA 360
      • 12.2.1 NORTH AMERICA: RECESSION IMPACT 360
      • 12.2.2 US 367
        • 12.2.2.1 Established reimbursement framework and favorable policies for IVD providers to drive market 367
      • 12.2.3 CANADA 373
        • 12.2.3.1 Favorable funding initiatives for early disease diagnosis to drive market 373
    • 12.3 EUROPE 380
      • 12.3.1 EUROPE: RECESSION IMPACT 381
      • 12.3.2 GERMANY 388
        • 12.3.2.1 Increasing investments in clinical diagnostics research to drive market 388
      • 12.3.3 FRANCE 394
        • 12.3.3.1 High healthcare expenditure and rising investments in genomic medicine to drive market 394
      • 12.3.4 UK 399
        • 12.3.4.1 Rising adoption of genome-based testing to drive market 399
      • 12.3.5 ITALY 406
        • 12.3.5.1 Growing geriatric population and subsequent rise in chronic conditions to support market growth 406
      • 12.3.6 SPAIN 412
        • 12.3.6.1 Rising adoption of technologically advanced immunoassay systems to drive market 412
      • 12.3.7 RUSSIA 417
        • 12.3.7.1 High incidence of respiratory infectious diseases to boost demand 417
      • 12.3.8 SWITZERLAND 423
        • 12.3.8.1 Rising prevalence of chronic diseases to support market growth 423
      • 12.3.9 REST OF EUROPE 429
    • 12.4 ASIA PACIFIC 436
      • 12.4.1 ASIA PACIFIC: RECESSION IMPACT 444
      • 12.4.2 JAPAN 444
        • 12.4.2.1 Increasing research investments for immunoassays to drive market 444
      • 12.4.3 CHINA 450
        • 12.4.3.1 Growing focus on preventive care to boost demand 450
      • 12.4.4 INDIA 455
        • 12.4.4.1 Rising incidence of diabetes and cancer to drive market 455
      • 12.4.5 SOUTH KOREA 461
        • 12.4.5.1 Rising healthcare spending for innovative IVD technologies to support market growth 461
      • 12.4.6 AUSTRALIA 467
        • 12.4.6.1 Increasing incidence of chronic diseases and rising blood donations to fuel market 467
      • 12.4.7 REST OF ASIA PACIFIC 474
    • 12.5 LATIN AMERICA 480
      • 12.5.1 LATIN AMERICA: RECESSION IMPACT 480
      • 12.5.2 BRAZIL 486
        • 12.5.2.1 Rising prevalence of diabetes to boost demand for IVD products 486
      • 12.5.3 MEXICO 491
        • 12.5.3.1 Establishment of clinical laboratories to fuel uptake 491
      • 12.5.4 REST OF LATIN AMERICA 497
    • 12.6 MIDDLE EAST & AFRICA 503
      • 12.6.1 GROWING FOCUS ON PRENATAL & CANCER TESTING TO DRIVE MARKET 503
      • 12.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 508
    • 12.7 GCC COUNTRIES 509
      • 12.7.1 GCC COUNTRIES: RECESSION IMPACT 509
      • 12.7.2 KINGDOM OF SAUDI ARABIA (KSA) 515
        • 12.7.2.1 Rising government healthcare expenditure to boost demand 515
      • 12.7.3 UNITED ARAB EMIRATES (UAE) 521
        • 12.7.3.1 Improvements in healthcare infrastructure to support market growth 521
      • 12.7.4 OTHER GCC COUNTRIES 527

  • 13 COMPETITIVE LANDSCAPE 533

    • 13.1 OVERVIEW 533
    • 13.2 STRATEGIES ADOPTED BY KEY PLAYERS 533
    • 13.3 REVENUE SHARE ANALYSIS OF LEADING MARKET PLAYERS 535
    • 13.4 MARKET SHARE ANALYSIS 536
    • 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 538
      • 13.5.1 STARS 538
      • 13.5.2 EMERGING LEADERS 538
      • 13.5.3 PERVASIVE PLAYERS 538
      • 13.5.4 PARTICIPANTS 538
      • 13.5.5 COMPANY FOOTPRINT ANALYSIS OF KEY PLAYERS 540
    • 13.6 START UP/SME EVALUATION MATRIX, 2023 544
      • 13.6.1 PROGRESSIVE COMPANIES 544
      • 13.6.2 RESPONSIVE COMPANIES 544
      • 13.6.3 DYNAMIC COMPANIES 544
      • 13.6.4 STARTING BLOCKS 544
      • 13.6.5 COMPETITIVE BENCHMARKING OF START-UPS/SMES 545
    • 13.7 COMPETITIVE SCENARIO 546
      • 13.7.1 PRODUCT & SERVICE LAUNCHES AND APPROVALS 546
      • 13.7.2 DEALS 547
      • 13.7.3 EXPANSIONS 548
      • 13.7.4 OTHER DEVELOPMENTS 549
    • 13.8 BRAND/PRODUCT COMPARISON 550

  • 14 COMPANY PROFILES 551

    • 14.1 KEY PLAYERS 551
      • 14.1.1 DANAHER CORPORATION 551
      • 14.1.2 ROCHE DIAGNOSTICS 558
      • 14.1.3 ABBOTT 568
      • 14.1.4 SIEMENS HEALTHINEERS AG 576
      • 14.1.5 THERMO FISHER SCIENTIFIC INC 583
      • 14.1.6 ILLUMINA, INC 591
      • 14.1.8 BIO-RAD LABORATORIES, INC 601
      • 14.1.9 BIOMÉRIEUX 606
      • 14.1.10 SYSMEX CORPORATION 612
      • 14.1.11 REVVITY 616
      • 14.1.12 BECTON, DICKINSON AND COMPANY 622
      • 14.1.13 AGILENT TECHNOLOGIES, INC 628
      • 14.1.14 QIAGEN N.V 635
      • 14.1.15 DIASORIN S.P.A 644
      • 14.1.16 GRIFOLS S.A 652
      • 14.1.17 WERFEN S.A 655
      • 14.1.18 QUIDELORTHO CORPORATION 659
    • 14.2 OTHER PLAYERS 666
      • 14.2.1 DEVYSER 666
      • 14.2.2 CHEMBIO DIAGNOSTICS, INC 668
      • 14.2.3 SURMODICS, INC 671
      • 14.2.4 MENARINI SILICON BIOSYSTEMS 674
      • 14.2.5 SPEEDX PTY. LTD 675
      • 14.2.6 GENSPEED BIOTECH GMBH 676
      • 14.2.7 MERCK KGAA 677
      • 14.2.8 CARIS LIFE SCIENCES, INC 679
      • 14.2.9 ARKRAY, INC 681
      • 14.2.10 ACCELERATE DIAGNOSTICS, INC 682
      • 14.2.11 CELLABS 683
      • 14.2.12 J. MITRA & CO. PVT. LTD 684
      • 14.2.13 EPITOPE DIAGNOSTICS, INC 685
      • 14.2.14 BOSTER BIOLOGICAL TECHNOLOGY 686
      • 14.2.15 ENZO BIOCHEM, INC 687
      • 14.2.16 GENETIC SIGNATURES 688
      • 14.2.17 SAVYON DIAGNOSTICS LTD 689
      • 14.2.18 TRIVITRON HEALTHCARE 690
      • 14.2.19 MDXHEALTH SA 691
      • 14.2.20 CREATIVE DIAGNOSTICS 692
      • 14.2.21 INBIOS INTERNATIONAL, INC 693
      • 14.2.22 MACCURA BIOTECHNOLOGY CO., LTD 694
      • 14.2.23 VELA DIAGNOSTICS 695

  • 15 APPENDIX 696

    • 15.1 DISCUSSION GUIDE 696
    • 15.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 703
    • 15.3 CUSTOMIZATION OPTIONS 705
    • 15.4 RELATED REPORTS 706
    • 15.5 AUTHOR DETAILS 707

TABLE 1 RISK ASSESSMENT ANALYSIS TABLE 2 ESTIMATED INCREASE IN GERIATRIC POPULATION, BY REGION (2022-2050) TABLE 3 IN VITRO DIAGNOSTICS MARKET: PRODUCT LAUNCHES (2021-2023) TABLE 4 APPLICATION OF CANCER BIOMARKERS IN CLINICAL PRACTICE TABLE 5 RECENT DEVELOPMENTS IN EMERGING MARKETS TABLE 6 IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES TABLE 7 IN VITRO DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS TABLE 8 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS TABLE 9 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES TABLE 10 EUROPE: CLASSIFICATION OF IVD DEVICES TABLE 11 JAPAN: CLASSIFICATION OF IVD REAGENTS IN JAPAN TABLE 12 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS TABLE 13 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS TABLE 14 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS TABLE 15 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES TABLE 16 RUSSIA: CLASSIFICATION OF IVD DEVICES TABLE 17 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS TABLE 18 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS TABLE 19 IN VITRO DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2024) TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IVD PRODUCTS (%) TABLE 21 KEY BUYING CRITERIA FOR IN VITRO DIAGNOSTIC PRODUCTS TABLE 22 IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2018-2022 (USD MILLION) TABLE 23 EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2018-2022 (USD MILLION) TABLE 24 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 25 IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY REGION, 2021-2029 (USD MILLION) TABLE 26 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 27 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 28 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 29 LATIN AMERICA: IN VITRO DIAGNOSTICS FOR REAGENTS & KITS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 30 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 31 KEY INSTRUMENTS AVAILABLE IN IVD MARKET TABLE 32 IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2021-2029 (USD MILLION) TABLE 33 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 34 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 35 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 36 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 37 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 38 KEY DATA MANAGEMENT SOFTWARE SOLUTIONS AVAILABLE IN IVD MARKET TABLE 39 IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE AND SERVICES, BY REGION, 2021-2029 (USD MILLION) TABLE 40 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE AND SERVICES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 41 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE AND SERVICES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 42 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE AND SERVICES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 43 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE AND SERVICES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 44 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE AND SERVICES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 45 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 46 KEY IMMUNOASSAY ANALYZERS AVAILABLE IN IVD MARKET TABLE 47 IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 48 IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2021-2029 (USD MILLION) TABLE 49 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 50 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2021-2029 ((USD MILLION) TABLE 51 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 52 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 53 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 54 KEY ELISA ANALYZERS AVAILABLE IN IVD MARKET TABLE 55 IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY REGION, 2021-2029 (USD MILLION) TABLE 56 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 57 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 58 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 59 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 60 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 61 KEY CHEMILUMINESCENCE IMMUNOASSAY SYSTEMS AVAILABLE IN IVD MARKET TABLE 62 IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY REGION, 2021-2029 (USD MILLION) TABLE 63 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 64 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 65 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 66 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 67 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 68 IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY REGION, 2021-2029 (USD MILLION) TABLE 69 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 70 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 71 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 72 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 73 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 74 KEY RAPID TESTS AVAILABLE IN IVD MARKET TABLE 75 IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY REGION, 2021-2029 (USD MILLION) TABLE 76 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 77 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 78 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 79 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 80 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 81 IN VITRO DIAGNOSTICS MARKET FOR ELISPOT, BY REGION, 2021-2029 (USD MILLION) TABLE 82 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELISPOT, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 83 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ELISPOT, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 84 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ELISPOT, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 85 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELISPOT, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 86 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET ELISPOT, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 87 KEY WESTERN BLOTTING SYSTEMS AVAILABLE IN IVD MARKET TABLE 88 IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY REGION, 2021-2029 (USD MILLION) TABLE 89 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 90 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 91 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 92 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 93 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 94 IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY REGION, 2021-2029 (USD MILLION) TABLE 95 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 96 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 97 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 98 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 99 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 100 CLINICAL CHEMISTRY ANALYZERS FOR HIGH AND MID-VOLUME LABORATORIES TABLE 101 CLINICAL CHEMISTRY ANALYZERS FOR LOW-VOLUME LABORATORIES TABLE 102 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 103 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY REGION, 2021-2029 (USD MILLION) TABLE 104 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 105 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 106 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 107 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 108 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 109 IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY REGION, 2021-2029 (USD MILLION) TABLE 110 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 111 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 112 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 113 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 114 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 115 IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY REGION, 2021-2029 (USD MILLION) TABLE 116 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 117 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 118 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 119 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 120 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 121 IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY REGION, 2021-2029 (USD MILLION) TABLE 122 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 123 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 124 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 125 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 126 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 127 IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY REGION, 2021-2029 (USD MILLION) TABLE 128 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 129 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 130 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 131 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 132 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 133 IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY REGION, 2021-2029 (USD MILLION) TABLE 134 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 135 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 136 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 137 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 138 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 139 IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY REGION, 2021-2029 (USD MILLION) TABLE 140 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 141 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 142 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 143 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 144 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 145 IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY REGION, 2021-2029 (USD MILLION) TABLE 146 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 147 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 148 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 149 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 150 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 151 KEY AUTOMATED MOLECULAR DIAGNOSTIC PLATFORMS AVAILABLE IN IVD MARKET TABLE 152 IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 153 IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2021-2029 (USD MILLION) TABLE 154 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 155 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 156 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 157 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 158 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 159 KEY PCR INSTRUMENTS AVAILABLE IN IVD MARKET TABLE 160 IN VITRO DIAGNOSTICS MARKET FOR PCR, BY REGION, 2021-2029 (USD MILLION) TABLE 161 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 162 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 163 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 164 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 165 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 166 IN VITRO DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2021-2029 (USD MILLION) TABLE 167 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 168 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 169 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 170 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 171 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 172 IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY REGION, 2021-2029 (USD MILLION) TABLE 173 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 174 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 175 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 176 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, 2021-2029 (USD MILLION) TABLE 177 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 178 IN VITRO DIAGNOSTICS MARKET FOR ISH, BY REGION, 2021-2029 (USD MILLION) TABLE 179 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 180 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 181 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 182 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 183 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 184 IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2021-2029 (USD MILLION) TABLE 185 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 186 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 187 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 188 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 189 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 190 IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY REGION, 2021-2029 (USD MILLION) TABLE 191 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 192 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 193 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 194 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 195 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 196 IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY REGION, 2021-2029 (USD MILLION) TABLE 197 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 198 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 199 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 200 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 201 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 202 IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY REGION, 2021-2029 (USD MILLION) TABLE 203 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 204 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 205 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 206 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 207 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 208 IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY REGION, 2021-2029 (USD MILLION) TABLE 209 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 210 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 211 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 212 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 213 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 214 IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY REGION, 2021-2029 (USD MILLION) TABLE 215 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 216 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 217 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 218 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 219 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 220 IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY REGION, 2021-2029 (USD MILLION) TABLE 221 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 222 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 223 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 224 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 225 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 226 IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 227 IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY REGION, 2021-2029 (USD MILLION) TABLE 228 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 229 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 230 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 231 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 232 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 233 IN VITRO DIAGNOSTICS MARKET FOR SALIVA, BY REGION, 2021-2029 (USD MILLION) TABLE 234 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SALIVA, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 235 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SALIVA, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 236 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SALIVA, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 237 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SALIVA, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 238 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SALIVA, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 239 IN VITRO DIAGNOSTICS MARKET FOR URINE, BY REGION, 2021-2029 (USD MILLION) TABLE 240 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINE, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 241 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR URINE, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 242 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR URINE, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 243 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINE, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 244 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR URINE, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 245 IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY REGION, 2021-2029 (USD MILLION) TABLE 246 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 247 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 248 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 249 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 250 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 251 IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 252 IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY REGION, 2021-2029 (USD MILLION) TABLE 253 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 254 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 255 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 256 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 257 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 258 IN VITRO DIAGNOSTICS MARKET FOR POC TESTS, BY REGION, 2021-2029 (USD MILLION) TABLE 259 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 260 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 261 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 262 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 263 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 264 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 265 IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2029 (USD MILLION) TABLE 266 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 267 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 268 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 269 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 270 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 271 INCREASING INCIDENCE OF CANCER, BY REGION, 2022 VS. 2040 TABLE 272 IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY REGION, 2021-2029 (USD MILLION) TABLE 273 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 274 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 275 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 276 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 277 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 278 IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY REGION, 2021-2029 (USD MILLION) TABLE 279 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 280 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 281 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 282 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 283 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 284 IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY REGION, 2021-2029 (USD MILLION) TABLE 285 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 286 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 287 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 288 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 289 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 290 IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY REGION, 2021-2029 (USD MILLION) TABLE 291 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 292 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 293 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 294 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 295 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 296 IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY REGION, 2021-2029 (USD MILLION) TABLE 297 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 298 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 299 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 300 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 301 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 302 IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2021-2029 (USD MILLION) TABLE 303 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 304 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 305 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 306 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 307 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 308 IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2021-2029 (USD MILLION) TABLE 309 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 310 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 311 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 312 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 313 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 314 KEY PRODUCTS FOR DRUG MONITORING TABLE 315 KEY IVD PRODUCTS FOR DRUG TESTING TABLE 316 IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY REGION, 2021-2029 (USD MILLION) TABLE 317 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 318 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 319 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 320 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 321 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 322 KEY PRODUCTS FOR BONE & MINERAL DISORDERS TABLE 323 IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2021-2029 (USD MILLION) TABLE 324 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 325 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 326 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 327 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 328 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 329 IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY REGION, 2021-2029 (USD MILLION) TABLE 330 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 331 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 332 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 333 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 334 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 335 IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY REGION, 2021-2029 (USD MILLION) TABLE 336 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 337 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 338 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 339 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 340 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 341 IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2029 (USD MILLION) TABLE 342 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 343 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 344 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 345 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 346 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 347 IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 348 IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021-2029 (USD MILLION) TABLE 349 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 350 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 351 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 352 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 353 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 354 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 355 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021-2029 (USD MILLION) TABLE 356 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 357 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 358 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 359 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 360 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 361 IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY REGION, 2021-2029 (USD MILLION) TABLE 362 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 363 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 364 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 365 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 366 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 367 IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY REGION, 2021-2029 (USD MILLION) TABLE 368 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 369 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 370 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 371 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 372 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 373 IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY REGION, 2021-2029 (USD MILLION) TABLE 374 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 375 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 376 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 377 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 378 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 379 IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY REGION, 2021-2029 (USD MILLION) TABLE 380 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 381 EUROPE: IVD MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 382 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 383 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 384 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 385 IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2029 (USD MILLION) TABLE 386 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 387 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 388 ASIA PACIFIC: IVD MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 389 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 390 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 391 IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2021-2029 (USD MILLION) TABLE 392 NORTH AMERICA: IVD MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 393 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 394 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 395 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 396 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 397 IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021-2029 (USD MILLION) TABLE 398 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 399 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 400 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 401 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 402 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 403 IN VITRO DIAGNOSTICS MARKET, BY REGION, 2021-2029 (USD MILLION) TABLE 404 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 405 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 406 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 407 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 408 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 409 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 410 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 411 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 412 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 413 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 414 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 415 US: MACROECONOMIC INDICATORS TABLE 416 US: NUMBER OF IN VITRO TESTS CONDUCTED (BILLION) TABLE 417 US: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 418 US: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 419 US: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 420 US: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 421 US: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 422 US: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 423 US: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 424 US: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 425 US: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 426 US: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 427 CANADA: ESTIMATED PREVALENCE OF DIABETES TABLE 428 CANADA: MACROECONOMIC INDICATORS TABLE 429 CANADA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 430 CANADA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 431 CANADA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 432 CANADA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 433 CANADA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 434 CANADA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 435 CANADA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 436 CANADA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 437 CANADA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 438 CANADA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 439 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 440 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 441 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 442 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 443 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 444 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 445 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 446 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 447 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 448 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 449 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 450 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 451 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 452 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 453 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 454 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 455 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 456 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 457 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 458 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 459 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 460 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 461 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 462 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 463 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 464 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 465 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 466 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 467 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 468 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 469 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 470 UK: MACROECONOMIC INDICATORS TABLE 471 UK: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 472 UK: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 473 UK: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 474 UK: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 475 UK: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 476 UK: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 477 UK: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 478 UK: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 479 UK: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 480 UK: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 481 ITALY: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 482 ITALY: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 483 ITALY: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 484 ITALY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 485 ITALY: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 486 ITALY: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 487 ITALY: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 488 ITALY: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 489 ITALY: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 490 ITALY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 491 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 492 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 493 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 494 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 495 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 496 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 497 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 498 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 499 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 500 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 501 RUSSIA: MACROECONOMIC INDICATORS TABLE 502 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 503 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 504 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 505 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 506 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 507 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 508 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 509 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 510 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 511 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 512 SWITZERLAND: MACROECONOMIC INDICATORS TABLE 513 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 514 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 515 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 516 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 517 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 518 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 519 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 520 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 521 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 522 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 523 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 524 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 525 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 526 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 527 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 528 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 529 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 530 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 531 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 532 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 533 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 534 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 535 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 536 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 537 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 538 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 539 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 540 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 541 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 542 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 543 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 544 JAPAN: MACROECONOMIC INDICATORS TABLE 545 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 546 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 547 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 548 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 549 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 550 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 551 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 552 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 553 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 554 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 555 CHINA: MACROECONOMIC INDICATORS TABLE 556 CHINA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 557 CHINA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 558 CHINA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 559 CHINA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 560 CHINA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 561 CHINA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 562 CHINA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 563 CHINA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 564 CHINA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 565 CHINA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 566 INDIA: MACROECONOMIC INDICATORS TABLE 567 INDIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 568 INDIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 569 INDIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 570 INDIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 571 INDIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 572 INDIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 573 INDIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 574 INDIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 575 INDIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 576 INDIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 577 SOUTH KOREA: MACROECONOMIC INDICATORS TABLE 578 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 579 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 580 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 581 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 582 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 583 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 584 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 585 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 586 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 587 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 588 AUSTRALIA: MACROECONOMIC INDICATORS TABLE 589 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 590 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 591 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 592 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 593 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 594 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 595 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 596 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 597 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 598 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 599 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 600 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 601 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 602 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 603 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 604 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 605 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 606 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 607 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 608 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 609 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 610 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 611 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 612 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 613 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 614 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 615 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 616 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 617 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 618 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 619 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 620 BRAZIL: MACROECONOMIC INDICATORS TABLE 621 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 622 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 623 BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 624 BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 625 BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 626 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 627 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 628 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 629 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 630 BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 631 MEXICO: MACROECONOMIC INDICATORS TABLE 632 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 633 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 634 MEXICO: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 635 MEXICO: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 636 MEXICO: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 637 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 638 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 639 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 640 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 641 MEXICO: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 642 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 643 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 644 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 645 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 646 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 647 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 648 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 649 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 650 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 651 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 652 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 653 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 654 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 655 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 656 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 657 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 658 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 659 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 660 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 661 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 662 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2021-2029 (USD MILLION) TABLE 663 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 664 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 665 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 666 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 667 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 668 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 669 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 670 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 671 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 672 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 673 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 674 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 675 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 676 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 677 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 678 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 679 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 680 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 681 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 682 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 683 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 684 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 685 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 686 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 687 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 688 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 689 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 690 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 691 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 692 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 693 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION) TABLE 694 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) TABLE 695 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION) TABLE 696 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION) TABLE 697 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION) TABLE 698 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION) TABLE 699 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION) TABLE 700 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION) TABLE 701 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION) TABLE 702 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION) TABLE 703 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN IVD MARKET TABLE 704 IN VITRO DIAGNOSTICS MARKET: INTENSITY OF COMPETITIVE RIVALRY TABLE 705 COMPANY FOOTPRINT ANALYSIS TABLE 706 COMPANY PRODUCT & SERVICE FOOTPRINT TABLE 707 COMPANY TECHNOLOGY FOOTPRINT TABLE 708 COMPANY APPLICATION FOOTPRINT TABLE 709 IN VITRO DIAGNOSTICS MARKET: KEY START-UPS/SMES TABLE 710 IN VITRO DIAGNOSTICS MARKET: PRODUCT & SERVICE LAUNCHES AND APPROVALS (JANUARY 2020-JANUARY 2024) TABLE 711 IN VITRO DIAGNOSTICS MARKET: DEALS (JANUARY 2020-JANUARY 2024) TABLE 712 IN VITRO DIAGNOSTICS MARKET: EXPANSIONS (JANUARY 2020-JANUARY 2024) TABLE 713 IN VITRO DIAGNOSTICS MARKET: OTHER DEVELOPMENTS (JANUARY 2020-JANUARY 2024) TABLE 714 BRAND/PRODUCT COMPARISON FOR IN VITRO DIAGNOSTICS INSTRUMENTS TABLE 715 DANAHER: COMPANY OVERVIEW TABLE 716 ROCHE DIAGNOSTICS: COMPANY OVERVIEW TABLE 717 ABBOTT: COMPANY OVERVIEW TABLE 718 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW TABLE 719 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW TABLE 720 ILLUMINA, INC.: COMPANY OVERVIEW TABLE 721 HOLOGIC, INC.: COMPANY OVERVIEW TABLE 722 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW TABLE 723 BIOMÉRIEUX: COMPANY OVERVIEW TABLE 724 SYSMEX CORPORATION: COMPANY OVERVIEW TABLE 725 REVVITY: COMPANY OVERVIEW TABLE 726 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW TABLE 727 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW TABLE 728 QIAGEN N.V.: COMPANY OVERVIEW TABLE 729 DIASORIN S.P.A: COMPANY OVERVIEW TABLE 730 GRIFOLS S.A: COMPANY OVERVIEW TABLE 731 WERFEN S.A: COMPANY OVERVIEW TABLE 732 QUIDELORTHO CORPORATION: COMPANY OVERVIEW TABLE 733 DEVYSER: COMPANY OVERVIEW TABLE 734 CHEMBIO DIAGNOSTICS, INC.: COMPANY OVERVIEW TABLE 735 SURMODICS, INC.: COMPANY OVERVIEW TABLE 736 MENARINI SILICON BIOSYSTEMS: COMPANY OVERVIEW TABLE 737 SPEEDX PTY. LTD.: COMPANY OVERVIEW TABLE 738 GENSPEED BIOTECH GMBH: COMPANY OVERVIEW TABLE 739 MERCK KGAA: COMPANY OVERVIEW TABLE 740 CARIS LIFE SCIENCES, INC.: COMPANY OVERVIEW TABLE 741 ARKRAY, INC.: COMPANY OVERVIEW TABLE 742 ACCELERATE DIAGNOSTICS, INC.: COMPANY OVERVIEW TABLE 743 CELLABS: COMPANY OVERVIEW TABLE 744 MITRA & CO. PVT. LTD.: COMPANY OVERVIEW TABLE 745 EPITOME DIAGNOSTICS, INC.: COMPANY OVERVIEW TABLE 746 BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW TABLE 747 ENZO BIOCHEM, INC: COMPANY OVERVIEW TABLE 748 GENETIC SIGNATURES: COMPANY OVERVIEW TABLE 749 SAVYON DIAGNOSTICS LTD.: COMPANY OVERVIEW TABLE 750 TRIVITRON HEALTHCARE: COMPANY OVERVIEW TABLE 751 MDXHEALTH SA: COMPANY OVERVIEW TABLE 752 CREATIVE DIAGNOSTICS: COMPANY OVERVIEW TABLE 753 INBIOS INTERNATIONAL, INC.: COMPANY OVERVIEW TABLE 754 MACCURA BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW TABLE 755 VELA DIAGNOSTICS: COMPANY OVERVIEW

FIGURE 1 MARKET SEGMENTATION FIGURE 2 RESEARCH DESIGN FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION FIGURE 5 REVENUE SHARE ANALYSIS FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS FIGURE 7 IN VITRO DIAGNOSTICS MARKET: TOP-DOWN APPROACH FIGURE 8 DATA TRIANGULATION METHODOLOGY FIGURE 9 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION) FIGURE 10 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION) FIGURE 11 IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2024 VS. 2029 (USD MILLION) FIGURE 12 IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2024 VS. 2029 (USD MILLION) FIGURE 13 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION) FIGURE 14 IN VITRO DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) FIGURE 15 GEOGRAPHIC SNAPSHOT OF IVD MARKET FIGURE 16 GROWING FOCUS ON EARLY DISEASE DIAGNOSIS TO DRIVE MARKET FIGURE 17 REAGENTS & KITS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 FIGURE 18 ASIA PACIFIC TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD FIGURE 19 CHINA AND INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD FIGURE 20 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD FIGURE 21 IN VITRO DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FIGURE 22 IVDR: CRITICAL AREAS OF IMPACT FIGURE 23 IN VITRO DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS FIGURE 24 IN VITRO DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS FIGURE 25 IN VITRO DIAGNOSTICS MARKET: ECOSYSTEM MAP FIGURE 26 US: REGULATORY PROCESS FOR IVD DEVICES FIGURE 27 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA FIGURE 28 EUROPE: IVDR TIMELINE FIGURE 29 REGULATORY PROCESS FOR IVD DEVICES IN JAPAN FIGURE 30 INDIA: REGULATORY PROCESS FOR IVD DEVICES FIGURE 31 MEXICO: REGULATORY PROCESS FOR IVD DEVICES FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR IVD PRODUCTS FIGURE 33 KEY BUYING CRITERIA FOR IVD PRODUCTS FIGURE 34 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET SNAPSHOT FIGURE 35 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET SNAPSHOT FIGURE 36 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN IVD MARKET FIGURE 37 IN VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2023) FIGURE 38 COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2023 FIGURE 39 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2023 FIGURE 40 DANAHER: COMPANY SNAPSHOT (2023) FIGURE 41 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2023) FIGURE 42 ABBOTT: COMPANY SNAPSHOT (2023) FIGURE 43 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023) FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023) FIGURE 45 ILLUMINA, INC.: COMPANY SNAPSHOT (2023) FIGURE 46 HOLOGIC, INC.: COMPANY SNAPSHOT (2023) FIGURE 47 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023) FIGURE 48 BIOMÉRIEUX: COMPANY SNAPSHOT (2023) FIGURE 49 SYSMEX CORPORATION: COMPANY SNAPSHOT (2023) FIGURE 50 REVVITY: COMPANY SNAPSHOT (2023) FIGURE 51 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023) FIGURE 52 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023) FIGURE 53 QIAGEN N.V.: COMPANY SNAPSHOT (2023) FIGURE 54 DIASORIN S.P.A: COMPANY SNAPSHOT (2023) FIGURE 55 GRIFOLS S.A: COMPANY SNAPSHOT (2023) FIGURE 56 WERFEN S.A: COMPANY SNAPSHOT (2023) FIGURE 57 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2023) FIGURE 58 DEVYSER: COMPANY SNAPSHOT (2023) FIGURE 59 CHEMBIO DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2022) FIGURE 60 SURMODICS, INC.: COMPANY SNAPSHOT (2023)

価格：USD 4,950
734,283円 もしくは部分購入
適用レート
1 USD = 148.34円
※稀に出版元により価格が改定されている場合がございます。
contact
© 2023 ShareFair Inc.